Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Saved in:
| Title: | Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. |
|---|---|
| Authors: | Kowdley KV; Liver Institute Northwest, Seattle, WA, USA; Elson S Floyd College of Medicine, Washington State University, Seattle, WA, USA. Electronic address: kkowdley@liverinstitutenw.org., Modi NB; Protagonist Therapeutics, Newark, CA, USA., Peltekian K; Division of Digestive Care and Endoscopy, Department of Medicine, Dalhousie University, Halifax, NS, Canada., Vierling JM; Section of Gastroenterology and Hepatology and Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, USA., Ferris C; Tryon Medical Partners, Charlotte, NC, USA., Valone FH; Protagonist Therapeutics, Newark, CA, USA., Gupta S; Protagonist Therapeutics, Newark, CA, USA. |
| Source: | The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2023 Dec; Vol. 8 (12), pp. 1118-1128. Date of Electronic Publication: 2023 Oct 17. |
| Publication Type: | Clinical Trial, Phase II; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
